IGM Biosciences Inc. (IGMS) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 26, 2020 4:06 PM EDT- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkins lymphoma expected in the second half of 2020 -
- IND filing for IGM-8444 planned in 2020 -
- Company to host conference call today at 4:30 p.m. ET -
MOUNTAIN VIEW, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Â IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company... More
